Top

Published in:

01-12-2021 | Hepatitis B | Review Article

Hepatitis B Before and After Hepatocellular Carcinoma

Authors: Murat Harputluoglu, Brian I. Carr

Published in: Journal of Gastrointestinal Cancer | Issue 4/2021

Abstract

Hepatitis B virus (HBV) is the one of most common causes of the hepatocellular carcinoma (HCC), especially in eastern world. The aim of this review is to try to understand the relationship between HBV and HCC and to reveal the role of prevention and treatment of HBV infection in reducing the incidence of HCC. Strategies to prevent HCC due to HBV can be classified into three categories. These are primary, secondary, and tertiary preventions. Hepatitis B vaccine is now in the most vital position in preventing HBV-associated HCC. In patients with chronic hepatitis B infection, suppressing viral load with potent antivirals such as tenofovir disoproxil fumarate (TDF) and entecavir (ETV) prevents the development of HCC and improves prognosis by reducing recurrence after HCC treatments. There is currently no clear consensus on which of these drugs should be preferred. Although data on tenofovir alafenamide (TAF) are scarce, available data with TDF suggest that TAF therapy will also be a strong actor for HCC.

Asafo-Agyei KO, Samant H. Hepatocellular carcinoma. Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021 PMID: 32644603.

Suresh D, Srinivas AN, Kumar DP. Etiology of hepatocellular carcinoma: special focus on fatty liver disease. Front Oncol. 2020;30: 601710. https://doi.org/10.3389/fonc.2020.601710.PMID:33330100;PMCID:PMC7734960.CrossRef

Madihi S, Syed H, Lazar F, Zyad A, Benani A. A systematic review of the current hepatitis B viral infection and hepatocellular carcinoma situation in Mediterranean countries. Biomed Res Int. 2020;2020:7027169. https://doi.org/10.1155/2020/7027169.PMID:32626758;PMCID:PMC7305551.CrossRefPubMedPubMedCentral

Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev. 2018;27:205–12. https://doi.org/10.1097/CEJ.0000000000000428.PMID:29489473;PMCID:PMC5876122.CrossRefPubMedPubMedCentral

Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 2016;22:319–326. https://doi.org/10.3350/cmh.2016.0045. Epub 2016 Sep 25. PMID: 27729632; PMCID: PMC5066383.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14. https://doi.org/10.1016/S0140-6736(18)30010-2 (Epub 2018 Jan 5 PMID: 29307467).CrossRefPubMed

Lin CL, Kao JH. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2018;48:5–14. https://doi.org/10.1111/apt.14683 (Epub 2018 May 3 PMID: 29722445).CrossRefPubMed

Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis. 2002;2:395–403.CrossRef

Xie Y. Hepatitis B virus-associated hepatocellular carcinoma. Adv Exp Med Biol. 2017;1018:11–21. https://doi.org/10.1007/978-981-10-5765-6_2 (PMID: 29052129).CrossRefPubMed

10.

Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Taiwan Community-Based Cancer Screening Project Group. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–74.CrossRef

11.

Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Child Hepatoma Study Group. New England J Med. 1997;336:1855–9.CrossRef

12.

Greenup AJ, Tan PK, Nguyen V, Glass A, Davison S, Chatterjee U, Holdaway S, Samarasinghe D, Jackson K, Locarnini SA, Levy MT. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502–7.CrossRef

13.

Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, Zhang H, Zou H, Zhu B, Zhao W, Jiang H, China Study Group for the Mother-to-Child Transmission of Hepatitis B. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016;374:2324–34.CrossRef

14.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–99. https://doi.org/10.1002/hep.29800.PMID:29405329;PMCID:PMC5975958.CrossRefPubMed

15.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–98. https://doi.org/10.1016/j.jhep.2017.03.021 (Epub 2017 Apr 18 PMID: 28427875).CrossRef

16.

Greenberg DP. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunogenicity studies. Pediatr Infect Dis J. 1993;12:438–45.CrossRef

17.

Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH, Group R-HS. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73.CrossRef

18.

Chen CJ, Yang HI, Iloeje UH, Group R-HS. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49:S72–84.CrossRef

19.

Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ, Mok TS. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177–82.CrossRef

20.

Lai CL, Yuen MF. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57:399–408.CrossRef

21.

Liaw YF. Impact of therapy on the outcome of chronic hepatitis B. Liver Int. 2013;33:111–5.CrossRef

22.

Liaw YF, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.CrossRef

23.

Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956–67.CrossRef

24.

Hosaka T, Suzuki F, Kobayashi M, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology. 2013;58:98–107.CrossRef

25.

Su TH, Hu TH, Chen CY, et al. C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016;36:1755–64.CrossRef

26.

Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, Flaherty JF, Martins EB, Therneau TM, Jacobson I, Fung S, Gurel S, Buti M, Marcellin P. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121:3631–8. https://doi.org/10.1002/cncr.29537 (Epub 2015 Jul 15 PMID: 26177866).CrossRefPubMed

27.

Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444–53.CrossRef

28.

Zhang Z, Zhou Y, Yang J, Hu K, Huang Y. The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis. BMC Cancer. 2019;19:511. https://doi.org/10.1186/s12885-019-5735-9.PMID:31142283;PMCID:PMC6542001.CrossRefPubMedPubMedCentral

29.

Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:246-258.e9. https://doi.org/10.1016/j.cgh.2020.05.008 (Epub 2020 May 11 PMID: 32407970).CrossRefPubMed

30.

Yip TC, Lai JC, Wong GL. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol 2020;55:1023–1036. https://doi.org/10.1007/s00535-020-01726-3. Epub 2020 Sep 24. PMID: 32974760; PMCID: PMC7567686.

31.

Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:1039–1052. https://doi.org/10.1016/S2468-1253(20)30249-1. Epub 2020 Sep 30. Erratum in: Lancet Gastroenterol Hepatol. 2021 Feb;6(2):e1. PMID: 33007228.

32.

Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B. J Viral Hepat 2021;26. https://doi.org/10.1111/jvh.13601. Epub ahead of print. PMID: 34435412.

33.

Lee HW, Cho YY, Lee H, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK, Park SY. Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B. Hepatol Int 2021;16. https://doi.org/10.1007/s12072-021-10234-2. Epub ahead of print. PMID: 34402025.

34.

Yip TC-F, Wong GL-H, Chan HL-Y, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol. 2019;70:361–70.CrossRef

35.

Kim G, Lim Y, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63:1325–32.CrossRef

36.

Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302–11.CrossRef

37.

Liang KH, Hsu CW, Chang ML, Chen YC, Lai MW, Yeh CT. Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B. J Infect Dis. 2016;213:966–74.CrossRef

38.

Ren P, Cao Z, Mo R, et al. Interferon-based treatment is superior to nucleos(t)ide analog in reducing HBV-related hepatocellular carcinoma for chronic hepatitis B patients at high risk. Expert Opin Biol Ther. 2018;18:1085–94. https://doi.org/10.1080/14712598.2018.1518423 (Epub 2018 Sep 13 PMID: 30182763).CrossRefPubMed

39.

Zhang W, Zhang B, Chen XP. Adjuvant treatment strategy after curative resection for hepatocellular carcinoma. Front Med. 2021;15:155–69. https://doi.org/10.1007/s11684-021-0848-3 (Epub 2021 Mar 23 PMID: 33754281).CrossRefPubMed

40.

Li MR, Chen GH, Cai CJ, Wang GY, Zhao H. High hepatitis B virus DNA level in serum before liver transplantation increases the risk of hepatocellular carcinoma recurrence. Digestion. 2011;84:134–141. PMID: 21502763. https://doi.org/10.1159/000324197

41.

Kuzuya T, Katano Y, Kumada T, et al. (2007) Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22:1929–35.CrossRef

42.

Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010;17:179–85.CrossRef

43.

Zhang G, Yu X, Liu P, Huang X, Jiang X. Efficacy of nucleoside analogs for chronic hepatitis B virus-related hepatocellular carcinoma after curative treatment: a meta-analysis. Dig Dis Sci. 2018;63:3207–19.CrossRef

44.

Chen XX, Cheng JW, Huang A, Zhang X, Wang J, Fan J, Zhou J, Yang XR. The effect of antiviral therapy on patients with hepatitis B virus-related hepatocellular carcinoma after curative resection: a systematic review and meta-analysis. OncoTargets Ther. 2017;10:5363–75.CrossRef

45.

Yuan P, Chen P, Qian Y. Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: an updated meta-analysis. Can J Gastroenterol Hepatol. 2016;2016:5234969.PubMedPubMedCentral

46.

Liu GM, Huang XY, Shen SL, Hu WJ, Peng BG. Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis. Hepatol Res. 2016;46:100–10.CrossRef

47.

Wong JS, Wong GL, Tsoi KK, Wong VW, Cheung SY, Chong CN, Wong J, Lee KF, Lai PB, Chan HL. Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther. 2011;33:1104–1112. [PMID: 21488914: https://doi.org/10.1111/j.1365-2036.2011.04634.x]

48.

Jian ZW, Wu XW, Chen ZX, Wang JC, Peng JY, Lao XM. Effect of nucleos(t)ide analogs on patients with intermediate and advanced hepatitis B virus-related hepatocellular carcinoma. Dig Dis Sci. 2019;64:2187–98. https://doi.org/10.1007/s10620-019-05543-4 (Epub 2019 Feb 28 PMID: 30815819).CrossRefPubMed

49.

Choi J, Jo C, Lim YS. Tenofovir versus entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. Hepatology. 2021;73:661–73. https://doi.org/10.1002/hep.31289 (Epub 2020 Nov 2 PMID: 32324905).CrossRefPubMed

50.

Zhang X, Li C, Wen T, Yan L, Yang J, Tang H, Lu C. The different effects of nucleotide and nucleoside analogues on the prognosis of HBV-related HCC after curative resection. J Gastrointest Surg. 2021;25:1419–29. https://doi.org/10.1007/s11605-020-04633-3 (Epub 2020 May 14 PMID: 32410175).CrossRefPubMed

51.

Huang G, Yang Y, Shen F, Pan ZY, Fu SY, Lau WY, et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Annals of Surgical Oncology. 2013;20:1482–1490. https://doi.org/10.1245/s10434-012-2803-7.

52.

Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, et al. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med. 2021;89:48–55. https://doi.org/10.1016/j.ejim.2021.02.019. Epub 2021 Mar 31. PMID: 33810942.

53.

Li M, Lu C, Cheng J, Zhang J, Cao C, Xu J, Xu J, Pan H, Zhong B, Tucker S, Wang D. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma. J Gastroenterol Hepatol. 2009;24:1437–44. https://doi.org/10.1111/j.1440-1746.2009.05863.x (Epub 2009 May 28 PMID: 19486255).CrossRefPubMed

Title: Hepatitis B Before and After Hepatocellular Carcinoma
Authors: Murat Harputluoglu
Brian I. Carr
Publication date: 01-12-2021
Publisher: Springer US
Keywords: Hepatitis B
Liver Resection
Liver Resection
Tenofovir
Entecavir
Lamivudine
Hepatocellular Carcinoma
Hepatocellular Carcinoma
Interferon
Lamivudine
Published in: Journal of Gastrointestinal Cancer / Issue 4/2021
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-021-00745-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Hepatitis B/D-Related Hepatocellular Carcinoma. A Clinical Literature Review

Prognostic Factors of Liver Transplantation for HCC: Comparative Literature Review

Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma

The Gut Microbiome and Hepatocellular Carcinoma

Surveillance Strategies for Hepatocellular Carcinoma: Recent Advances and the Shifting Paradigm

The Importance of the Immunosuppressive Regime on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage